Lead Plaintiff Deadline: January 04, 2022
See If You Qualify For Monetary Reward
Please Upload related files below
Fill in below.
Looking for more?
(a) common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company’s initial public offering conducted on or about December 3, 2020 and/or (b) securities between December 3, 2020 and September 10, 2021, both dates inclusive
(i) Silverback’s lead product candidate SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers, was less effective than the Company had represented to investors; (ii) accordingly, the Company had overstated SBT6050’s commercial and/or clinical prospects; and (iii) as a result, the Offering Documents and Defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.
In order to be included in the lawsuit, you must have incurred a loss on shares of Silverback Therapeutics purchased or acquired during the class period listed above.
If you suffered a loss in Silverback Therapeutics during the relevant time frame, you have until January 04, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.